The Quest Diagnostics blood test, AD-Detect, measures elevated levels of amyloid-beta proteins, a signature characteristic of Alzheimer’s.
But Alzheimer’s researchers and clinicians aren’t convinced the Quest test is backed by sound scientific research.
Though blood tests for Alzheimer’s are likely to become common in the years ahead, the Alzheimer’s Association said it’s premature to offer a test of this kind directly to consumers.
Because the science behind blood tests for Alzheimer’s is still developing and because “patients may not really understand the uncertainty of test results,” Edelmayer said, the Alzheimer’s Association “does not endorse the use of the AD-Detect test by consumers.”Quest’s blood test is one of several developments altering the landscape of Alzheimer’s care in the United States.
The bottom line: Before taking a test, “older adults need to ask themselves, ‘Why do I want to know this?
Persons:
aren’t, Alzheimer’s, Michael Racke, ”, there’s, Suzanne Schindler, St . Louis, That’s, ” Schindler, Racke, Meera Sheffrin, —, Rebecca Edelmayer, ” Edelmayer, Eric Widera, Dr, Sanjay Gupta, Emily Largent, ’ ”, Munro Cullum
Organizations:
Health, Diagnostics, Alzheimer’s Association, Quest, University of Michigan, International Conference, Washington University School of Medicine, Senior, Stanford Healthcare, The University of Michigan, FDA, National Institute, Aging, University of California, Get CNN, CNN Health, University, Pennsylvania’s Perelman, of Medicine, HIPAA, University of Texas Southwestern Medical Center, Kaiser Health, KFF
Locations:
U.S, San Diego, St ., United States, San Francisco